C5 and dry age related macular degeneration: While eculizumab, a humanized IgG antibody against complement component 5 (C5), seems to be ineffective in the management of dry AMD patients [180], treatment with lampalizumab, an antibody that inhibits complement factor D, reduced the progression of geographic atrophy lesion [181].